netrashetty
Netra Shetty
Abraxis BioScience is a global biopharmaceutical company dedicated to meeting the needs of critically ill patients, with over 2000 employees worldwide.[1]
[edit]
Patrick Soon-Shiong, a self-made billionaire through injectable and breakthrough nanoparticle anticancer technology drug development, is now focusing his philanthropic efforts on creating a national highway for health care. He is donating $1 billion of the $3 billion he netted from the $5.6 billion sale of APP Pharmaceuticals to create the Bell Labs of Health Care. His goal is to build a smart grid for health care, which aims to not only provide greater transparency for doctors and patients to better identify ailments and treatments, but to also eliminate fraud and abuse in today's health care system.
Patrick Soon-Shiong: The idea is to create a health grid that empowers the patient and the provider. This should be a public utility, basically what I call a U.S. public health grid. If you look at swine flu, for example--we just presented this at the Institute of Medicine. If you look at swine flu, the world came together very quickly, where we actually were able to share, very quickly, the genomic DNA and actually identify how to actually address this, in a global sense. We need to treat chronic disease as an epidemic like the swine flu. But the only way you can do that, whether it's diabetes, whether it's heart disease and whether it's cancer, is to have what you call a grid, a public utility that you can actually share information on a national scale.
With the whole new era of molecular medicine, there's a whole new huge amount of information available today that can significantly impact the decision the doctor's making, that'll affect your life today. It's what I call actionable information. Which then set in motion for me a sense of urgency, that there is without question in my mind, the most important contribution that I can make, establish what I call an information highway. A public utility for information to be shared across the nation. To not only empower the doctor but empower the patient.
Patrick Soon-Shiong is Chairman and CEO of the global pharmaceutical company Abraxis BioScience Inc. A noted researcher, physician and surgeon, Soon-Shiong developed and co-invented the nanoparticle delivery technology upon which the cremophor-free form of paclitaxel compound known as Abraxane is based. Abraxane won FDA approval in 2005 for treatment of advanced metastatic breast cancer and is being developed for lung, ovarian, prostate, melanoma, and head and neck cancers. His research has been recognized by numerous national awards from such noted organizations as the Association for Academic Surgery, the American College of Surgeons Schering Award and the Royal College Physicians and Surgeons. Soon-Shiong serves on the board of directors for the National Institute of Transplantation and on the Technology Council for the new Center for Cancer Nanotechnology Excellence at Northwestern University. Soon-Shiong holds a degree in medicine from the University of the Witwatersrand, Johannesburg, South Africa, and an M.S. from the University of British Columbia. He is a fellow of the American College of Surgeons and the Royal College of Physicians and Surgeons of Canada.
HE's described as stubborn and opportunistic by critics, but praised by supporters as a gifted surgeon and entrepreneur of enormous energy and vision. Either way, Abraxis BioScience Chief Executive Patrick Soon-Shiong certainly developed a strong sense of self growing up the son of Chinese immigrants in apartheid-era South Africa. His father practiced Chinese herbal medicine and Soon-Shiong went on to break barriers as a doctor in South Africa's segregated medical community. He and his wife, actress Michele Chan, eventually moved to Los Angeles, where he worked at the UCLA School of Medicine. There he was involved in developing groundbreaking transplantation techniques to treat diabetes, and did research on ways to better deliver chemotherapy. That led to the technology behind Abraxane, a breast cancer drug made by Abraxis based on nanotechnology. Soon-Shiong has become a multibillionaire, with the recent sale of a separate generic drug business, APP Pharmaceuticals, increasing his estimated net worth to $5.3 billion. But throughout his business career, the headstrong entrepreneur has clashed with others, including colleagues; investors; and even his own brother, who sued him over a failed business deal. Soon-Shiong shrugs it all off and these days is focusing more of his time on philanthropic endeavors. He and his wife have pledged more than $55 million to Santa Monica's St. John's Health Center and are putting the finishing touches on a new family foundation.
KCET's 10th Visionary Award recipients are Patrick Soon-Shiong, M.D. and Michele B. Chan. Raised in South Africa under apartheid, Dr. Soon-Shiong and Ms. Chan experienced the challenges of discrimination earlyin life. They dedicated themselves to closing disparity gaps that exist in the world through a shared belief that innovation creates a catalyst for change.
patrick-soon-shiong.jpg
A renowned physician, surgeon, inventor, scientist,entrepreneur and philanthropist, Dr. Soon-Shiong has been at the forefront of medicine and health. He pioneered the revolutionary anticancer drug Abraxane®for treatment of metastatic breast cancer and founded the global pharmaceuticalcompany Abraxis BioScience, Inc.
Ms. Chan, a former film and television actress, not only supported her husband early in his career, she continues to actively support the healthcare community. Her interests include the areas of women's health, complementary and integrative medicine and neuroscience - all of which play arole in her efforts on behalf of Saint John's Health Center in Santa Monica.
As founders of the Chan Soon-Shiong Family Foundation, the couple has generously supported St. John's Health Center and the project under way to re-open Martin Luther King Jr. (MLK) Hospital in Los Angeles. With their support, Saint John's opened the Chan Soon-Shiong Center for life sciences, a next-generation facility for practicing 21st century medicine. Their commitment to MLK Hospital enabled the University of California Board of Regents to enter into a partnership with Los Angeles County creating a private,nonprofit corporation that will re-open the hospital.
[edit]
Patrick Soon-Shiong, a self-made billionaire through injectable and breakthrough nanoparticle anticancer technology drug development, is now focusing his philanthropic efforts on creating a national highway for health care. He is donating $1 billion of the $3 billion he netted from the $5.6 billion sale of APP Pharmaceuticals to create the Bell Labs of Health Care. His goal is to build a smart grid for health care, which aims to not only provide greater transparency for doctors and patients to better identify ailments and treatments, but to also eliminate fraud and abuse in today's health care system.
Patrick Soon-Shiong: The idea is to create a health grid that empowers the patient and the provider. This should be a public utility, basically what I call a U.S. public health grid. If you look at swine flu, for example--we just presented this at the Institute of Medicine. If you look at swine flu, the world came together very quickly, where we actually were able to share, very quickly, the genomic DNA and actually identify how to actually address this, in a global sense. We need to treat chronic disease as an epidemic like the swine flu. But the only way you can do that, whether it's diabetes, whether it's heart disease and whether it's cancer, is to have what you call a grid, a public utility that you can actually share information on a national scale.
With the whole new era of molecular medicine, there's a whole new huge amount of information available today that can significantly impact the decision the doctor's making, that'll affect your life today. It's what I call actionable information. Which then set in motion for me a sense of urgency, that there is without question in my mind, the most important contribution that I can make, establish what I call an information highway. A public utility for information to be shared across the nation. To not only empower the doctor but empower the patient.
Patrick Soon-Shiong is Chairman and CEO of the global pharmaceutical company Abraxis BioScience Inc. A noted researcher, physician and surgeon, Soon-Shiong developed and co-invented the nanoparticle delivery technology upon which the cremophor-free form of paclitaxel compound known as Abraxane is based. Abraxane won FDA approval in 2005 for treatment of advanced metastatic breast cancer and is being developed for lung, ovarian, prostate, melanoma, and head and neck cancers. His research has been recognized by numerous national awards from such noted organizations as the Association for Academic Surgery, the American College of Surgeons Schering Award and the Royal College Physicians and Surgeons. Soon-Shiong serves on the board of directors for the National Institute of Transplantation and on the Technology Council for the new Center for Cancer Nanotechnology Excellence at Northwestern University. Soon-Shiong holds a degree in medicine from the University of the Witwatersrand, Johannesburg, South Africa, and an M.S. from the University of British Columbia. He is a fellow of the American College of Surgeons and the Royal College of Physicians and Surgeons of Canada.
HE's described as stubborn and opportunistic by critics, but praised by supporters as a gifted surgeon and entrepreneur of enormous energy and vision. Either way, Abraxis BioScience Chief Executive Patrick Soon-Shiong certainly developed a strong sense of self growing up the son of Chinese immigrants in apartheid-era South Africa. His father practiced Chinese herbal medicine and Soon-Shiong went on to break barriers as a doctor in South Africa's segregated medical community. He and his wife, actress Michele Chan, eventually moved to Los Angeles, where he worked at the UCLA School of Medicine. There he was involved in developing groundbreaking transplantation techniques to treat diabetes, and did research on ways to better deliver chemotherapy. That led to the technology behind Abraxane, a breast cancer drug made by Abraxis based on nanotechnology. Soon-Shiong has become a multibillionaire, with the recent sale of a separate generic drug business, APP Pharmaceuticals, increasing his estimated net worth to $5.3 billion. But throughout his business career, the headstrong entrepreneur has clashed with others, including colleagues; investors; and even his own brother, who sued him over a failed business deal. Soon-Shiong shrugs it all off and these days is focusing more of his time on philanthropic endeavors. He and his wife have pledged more than $55 million to Santa Monica's St. John's Health Center and are putting the finishing touches on a new family foundation.
KCET's 10th Visionary Award recipients are Patrick Soon-Shiong, M.D. and Michele B. Chan. Raised in South Africa under apartheid, Dr. Soon-Shiong and Ms. Chan experienced the challenges of discrimination earlyin life. They dedicated themselves to closing disparity gaps that exist in the world through a shared belief that innovation creates a catalyst for change.
patrick-soon-shiong.jpg
A renowned physician, surgeon, inventor, scientist,entrepreneur and philanthropist, Dr. Soon-Shiong has been at the forefront of medicine and health. He pioneered the revolutionary anticancer drug Abraxane®for treatment of metastatic breast cancer and founded the global pharmaceuticalcompany Abraxis BioScience, Inc.
Ms. Chan, a former film and television actress, not only supported her husband early in his career, she continues to actively support the healthcare community. Her interests include the areas of women's health, complementary and integrative medicine and neuroscience - all of which play arole in her efforts on behalf of Saint John's Health Center in Santa Monica.
As founders of the Chan Soon-Shiong Family Foundation, the couple has generously supported St. John's Health Center and the project under way to re-open Martin Luther King Jr. (MLK) Hospital in Los Angeles. With their support, Saint John's opened the Chan Soon-Shiong Center for life sciences, a next-generation facility for practicing 21st century medicine. Their commitment to MLK Hospital enabled the University of California Board of Regents to enter into a partnership with Los Angeles County creating a private,nonprofit corporation that will re-open the hospital.